| Literature DB >> 26759237 |
Fatéméh Dubois1, Maureen Keller1, Olivier Calvayrac2, Fabrice Soncin3, Lily Hoa4, Alexander Hergovich4, Maria-Carla Parrini5, Julien Mazières2, Mélissa Vaisse-Lesteven6, Jacques Camonis5, Guénaëlle Levallet7, Gérard Zalcman8.
Abstract
Inactivation of the tumor suppressor gene RASSF1A by promoter hypermethylation represents a key event underlying the initiation and progression of lung cancer. RASSF1A inactivation is also associated with poor prognosis and may promote metastatic spread. In this study, we investigated how RASSF1A inactivation conferred invasive phenotypes to human bronchial cells. RNAi-mediated silencing of RASSF1A induced epithelial-to-mesenchymal transition (EMT), fomenting a motile and invasive cellular phenotype in vitro and increased metastatic prowess in vivo. Mechanistic investigations revealed that RASSF1A blocked tumor growth by stimulating cofilin/PP2A-mediated dephosphorylation of the guanine nucleotide exchange factor GEF-H1, thereby stimulating its ability to activate the antimetastatic small GTPase RhoB. Furthermore, RASSF1A reduced nuclear accumulation of the Hippo pathway transcriptional cofactor Yes-associated protein (YAP), which was reinforced by RhoB activation. Collectively, our results indicated that RASSF1 acts to restrict EMT and invasion by indirectly controlling YAP nuclear shuttling and activation through a RhoB-regulated cytoskeletal remodeling process, with potential implications to delay the progression of RASSF1-hypermethylated lung tumors. ©2016 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26759237 DOI: 10.1158/0008-5472.CAN-15-1008
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701